Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.32%AUDUSD-1.14%GBPCHF+1.00%GBPCAD+0.83%USDCHF+0.80%AUDJPY-0.78%EURGBP-0.67%EURAUD+0.66%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.65%USDTHB+0.60%GBPJPY+0.56%AUDCAD-0.51%EURUSD-0.50%NZDUSD-0.49%GBPTRY+0.41%CHFJPY-0.38%USDJPY+0.38%AUDCHF-0.37%PLNJPY+0.34%GBPHKD+0.32%NZDCHF+0.31%EURCHF+0.30%NOKJPY+0.29%GBPMXN-0.28%USDTRY+0.28%CADJPY-0.26%SGDJPY+0.26%GBPZAR+0.18%GBPUSD+0.18%EURZAR+0.17%NZDCAD+0.16%USDILS+0.16%USDCNH-0.16%EURCAD+0.15%CADCHF+0.15%USDZAR+0.14%EURJPY-0.12%NZDMXN+0.12%CHFSGD+0.11%NZDJPY-0.09%USDMXN+0.09%CHFNOK+0.09%EURSGD+0.07%EURCNH+0.07%NZDSGD+0.07%GBPSGD+0.07%AUDDKK-0.06%EURNOK+0.06%USDDKK-0.05%CHFSEK+0.04%USDSEK-0.04%USDPLN-0.04%USDCOP-0.04%USDHKD+0.04%EURCZK-0.03%USDSGD+0.03%EURHKD+0.03%AUDSGD+0.02%EURNZD+0.01%USDNOK+0.01%EURSEK+0.01%AUDNOK0.00%EURDKK0.00%EURPLN0.00%XPTUSD-0.91%HG1-0.56%GAGUSD-0.46%XAGUSD-0.46%W1+0.39%GAUUSD-0.33%XAUUSD-0.33%UKOIL+0.28%C1+0.23%XNGUSD+0.13%USOIL+0.12%S1-0.10%BTCUSD-0.17%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.04%ZECUSDT+0.46%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.68%XLMUSD+2.39%BCHUSDT-0.29%UNIUSD-0.38%LTCUSD+0.07%HBARUSDT+1.48%SUIUSD+1.88%TONUSD+15.77%TAOUSDT+0.03%AAVEUSD-3.57%DOTUSDT+2.95%ICPUSDT-3.29%ONDOUSDT+0.37%WLDUSDT+10.51%ARBUSDT-0.49%JUPUSDT-0.50%ATOMUSDT+1.16%INJUSDT-2.54%STXUSDT+19.59%FETUSDT+3.82%SEIUSDT+0.33%PYTHUSDT-2.59%TIAUSDT-0.29%IMXUSDT+0.97%GRTUSDT+0.16%OPUSDT+1.31%WIFUSDT+3.04%IOTAUSDT+3.58%POLUSDT-4.29%AXSUSDT+0.85%FARTCOINUSDT-0.55%EOSUSDT+4.55%DYDXUSDT+3.91%GALAUSDT+5.20%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.32%AUDUSD-1.14%GBPCHF+1.00%GBPCAD+0.83%USDCHF+0.80%AUDJPY-0.78%EURGBP-0.67%EURAUD+0.66%USDCAD+0.65%GBPNZD+0.65%AUDNZD-0.65%USDTHB+0.60%GBPJPY+0.56%AUDCAD-0.51%EURUSD-0.50%NZDUSD-0.49%GBPTRY+0.41%CHFJPY-0.38%USDJPY+0.38%AUDCHF-0.37%PLNJPY+0.34%GBPHKD+0.32%NZDCHF+0.31%EURCHF+0.30%NOKJPY+0.29%GBPMXN-0.28%USDTRY+0.28%CADJPY-0.26%SGDJPY+0.26%GBPZAR+0.18%GBPUSD+0.18%EURZAR+0.17%NZDCAD+0.16%USDILS+0.16%USDCNH-0.16%EURCAD+0.15%CADCHF+0.15%USDZAR+0.14%EURJPY-0.12%NZDMXN+0.12%CHFSGD+0.11%NZDJPY-0.09%USDMXN+0.09%CHFNOK+0.09%EURSGD+0.07%EURCNH+0.07%NZDSGD+0.07%GBPSGD+0.07%AUDDKK-0.06%EURNOK+0.06%USDDKK-0.05%CHFSEK+0.04%USDSEK-0.04%USDPLN-0.04%USDCOP-0.04%USDHKD+0.04%EURCZK-0.03%USDSGD+0.03%EURHKD+0.03%AUDSGD+0.02%EURNZD+0.01%USDNOK+0.01%EURSEK+0.01%AUDNOK0.00%EURDKK0.00%EURPLN0.00%XPTUSD-0.91%HG1-0.56%GAGUSD-0.46%XAGUSD-0.46%W1+0.39%GAUUSD-0.33%XAUUSD-0.33%UKOIL+0.28%C1+0.23%XNGUSD+0.13%USOIL+0.12%S1-0.10%BTCUSD-0.17%ETHUSD+7.44%USDTUSD-0.02%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.04%ZECUSDT+0.46%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.68%XLMUSD+2.39%BCHUSDT-0.29%UNIUSD-0.38%LTCUSD+0.07%HBARUSDT+1.48%SUIUSD+1.88%TONUSD+15.77%TAOUSDT+0.03%AAVEUSD-3.57%DOTUSDT+2.95%ICPUSDT-3.29%ONDOUSDT+0.37%WLDUSDT+10.51%ARBUSDT-0.49%JUPUSDT-0.50%ATOMUSDT+1.16%INJUSDT-2.54%STXUSDT+19.59%FETUSDT+3.82%SEIUSDT+0.33%PYTHUSDT-2.59%TIAUSDT-0.29%IMXUSDT+0.97%GRTUSDT+0.16%OPUSDT+1.31%WIFUSDT+3.04%IOTAUSDT+3.58%POLUSDT-4.29%AXSUSDT+0.85%FARTCOINUSDT-0.55%EOSUSDT+4.55%DYDXUSDT+3.91%GALAUSDT+5.20%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
CT

Corcept Therapeutics Incorporated (CORT)

NASDAQ • Healthcare

$115.23
+$0.49 (+0.4%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$114.8
Day Range$113.98 - $117.94
Avg. Volume (3M)1.7M
Market Cap$12.4B
P/E Ratio221.6
52 Week Range
$28.66$126.38
Next EarningsIn 34 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$256.1M100%
Gross Profitminus cost of goods$252M98%
Operating Incomeminus R&D and overhead$41.3M16%
Net Incomeminus taxes and the rest$42.1M16%

In plain terms: out of every $100 in revenue, Corcept Therapeutics Incorporated keeps $16 as net profit.

Fundamentals & Financials

Revenue (TTM)
$830.8M
Net Income (TTM)
$54.8M
EPS (TTM)
$0.52
ROA (TTM)
6.18%
Current Ratio
2.86

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-39.4%Q1 2026$0.2
-172.3%Q2 2026-$0.3
+1383.3%Q3 2026$0.36
Next

Nov 4

in 34 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a U.S. pharmaceutical company focused on cortisol modulation. Its business today centers on Korlym, an oral medication taken once daily, and it generated $761.4 million of revenue in FY2025 from operations in the healthcare sector.

Name
Corcept Therapeutics Incorporated
CEO
Joseph K. Belanoff
Website
www.corcept.com
Industry
Healthcare
Year Founded
1998
Employees
730

Today's Snapshot

AI-generated

CORT ended the day slightly higher at 115.23, while its sector was weaker. Volume was about a third of its usual level. Corcept shared a study update on miricorilant, its drug candidate for fatty liver disease.

Trading Volume

Below 10d avg (2.6M)

875.6K

vs S&P 500 Today

Moderate Outperformance

+0.24%

Updated: September 30, 2026 at 20:03 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
CORT is trading just above its short- and medium-term averages while remaining well above the long-term trend, which supports the buy stance; momentum indicators are mildly positive and price sits near the upper Bollinger range, however trend strength is limited with an ADX under 20 and on-balance volume shows distribution. Volatility is moderate, with an ATR around 4.6% that underscores intraday range but not extreme swings, and the classic pivot lies slightly above current levels. Technical takeaway: modest buy bias as price holds above key moving averages but trend conviction is muted.
All signals
  • EMA (5 indicators)$81.95 - $114.97
    Buy
  • RSI (14)52.59
    Neutral
  • Stochastic %K (14, 3, 3)56.23
    Neutral
  • MACD Level (12, 26)1.04
    Neutral

Peers & Related Assets

JAZZJazz Pharmaceuticals plc
$231.52-0.4%
HALOHalozyme Therapeutics, Inc.
$110.4-1.0%
AXSMAxsome Therapeutics, Inc.
$184.39-0.9%
NUVLNuvalent, Inc.
$123.960.0%
CAICaris Life Sciences, Inc.
$30.63-2.9%
CYTKCytokinetics, Incorporated
$65.91+0.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.